YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Stock price

Equities

1558

CNE1000023R6

Pharmaceuticals

Delayed Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
10.88 HKD +0.55% Intraday chart for YiChang HEC ChangJiang Pharmaceutical Co., Ltd. -2.68% +14.65%

Financials

Sales 2023 6.29B 871M 6.82B Sales 2024 * 7B 968M 7.57B Capitalization 8.84B 1.22B 9.57B
Net income 2023 * 1.56B 216M 1.69B Net income 2024 * 1.92B 265M 2.07B EV / Sales 2023 1.21 x
Net Debt 2023 * 320M 44.33M 347M Net cash position 2024 * 4.01B 555M 4.35B EV / Sales 2024 * 0.69 x
P/E ratio 2023 *
5.64 x
P/E ratio 2024 *
4.61 x
Employees -
Yield 2023 *
0.5%
Yield 2024 *
2.74%
Free-Float 27.7%
More Fundamentals * Assessed data
Dynamic Chart
YiChang HEC ChangJiang Pharmaceutical's Profit Surges in 2023 MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yichang Hec Changjiang Pharmaceutical Expects Up to 2,627% Profit Surge in 2023 MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2023 CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Sunshine Lake Pharma Enter into Drug R&D Pipeline Cooperation Project Framework Agreement CI
HEC ChangJiang Pharmaceutical Increases Transaction Limits Under 2 Contracts MT
HEC ChangJiang Pharmaceutical's Insulin Injection Cleared for Market Launch in China MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Receives Approval for Mixed Protamine Human Insulin Injection from the China National Medical Products Administration CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.Approves Announces Executive Changes CI
HEC ChangJiang Pharmaceutical Returns to Profit on Surge in Anti-Viral Drug Sales MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China Greenlights New Drug Application for HEC ChangJiang Pharmaceutical's Hepatitis C Drug MT
National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Yiqibuvir Tablets CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Resignation of Chen Yangui as Executive Director CI
HEC ChangJiang Pharmaceutical Forecasts Surge in H1 Profit; Shares Rise 5% MT
More news
1 day+0.55%
1 week-2.68%
Current month+6.67%
1 month+9.35%
3 months+15.01%
6 months+70.53%
Current year+14.65%
More quotes
1 week
10.74
Extreme 10.74
11.20
1 month
8.90
Extreme 8.9
11.98
Current year
7.91
Extreme 7.91
11.98
1 year
6.02
Extreme 6.02
11.98
3 years
3.35
Extreme 3.35
11.98
5 years
3.35
Extreme 3.35
27.23
10 years
3.35
Extreme 3.35
27.23
More quotes
Managers TitleAgeSince
Chief Executive Officer 42 15-05-03
Director of Finance/CFO 49 18-02-22
Director/Board Member 49 09-10-31
Members of the board TitleAgeSince
Chairman 54 15-05-03
Chief Executive Officer 42 15-05-03
Director/Board Member 54 06-02-26
More insiders
Date Price Change Volume
24-03-28 10.88 +0.55% 814,400
24-03-27 10.82 -2.17% 945,000
24-03-26 11.06 +0.73% 1,352,400
24-03-25 10.98 -0.18% 935,000
24-03-22 11 -1.61% 2,022,200

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of pharmaceutical products. The Company is also engaged in the research and development, marketing and distribution of pharmaceuticals. The products of the Company include anti-viral drugs, endocrine and metabolic drugs and cardiovascular drugs. Its main products include Kewei, Ertongshu, Oumeining, Xinhaining and Xining.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.05 CNY
Average target price
10.47 CNY
Spread / Average Target
+4.23%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock YiChang HEC ChangJiang Pharmaceutical Co., Ltd. - Hong Kong S.E.